Delving deeper into the promising landscape shaped by Ontario’s innovative biosimilar regulations. Discover how these policies are fostering enhanced accessibility for patients and driving positive transformations in the pharmaceutical industry. There are a few similarities and a few differences between biosimilars and generic drugs. A generic drug is an exact copy of its reference …
President Gisela Carere, MBA, and CEO Adam Carere had another incredible experience, expanding their knowledge from the industry’s leading experts. We are grateful to be a part of the UNIBA Partners community, which is an owner-led, client-centric global network that provides insurance broking, risk management, and employee benefits solutions. UNIBA’s conferences feature keynote speakers, workshops, and panels on …
Our Executive Team’s UNIBA Learnings, Exciting Updates, and Industry News Read More »
Biosimilars have been a trending topic for the last decade. For the last 15 years, they have been authorized to use in the European Union. Ontario joined the initiative to expand the use of biosimilar medications, following British Columbia, Alberta, New Brunswick, Quebec, Northwest Territories, Nova Scotia, and Saskatchewan. Biosimilar drugs have been available in …
